<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03296150</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0149</org_study_id>
    <nct_id>NCT03296150</nct_id>
  </id_info>
  <brief_title>ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE</brief_title>
  <acronym>ADOPT-PRESTAGE</acronym>
  <official_title>ADOPT-PRESTAGE: Randomized Controlled Trial on Acceptability, Diffusion and Impact on Treatment Adherence and Persistence of the PRESTAGE Program (Program for Education and Support for Oral Cancer Treatments in the Elderly) - Randomized Controlled Study Evaluating the Impact of the Program PRESTAGE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As the proportion of oral anticancer treatments is continuously increasing, adherence appears
      as a major issue for patients' outcomes. Poor adherence affects particularly geriatric
      patients due among others to polypharmacy or cognitive impairment. Thus, the need for
      educational programs in this population has been regularly emphasized.

      PRESTAGE educational program was built after an external and internal analysis of educational
      needs in elderly patients treated with oral cancer treatments. It implicates a
      multidisciplinary educational team (nurses, physicians, pharmacists, psychologists,
      physiologists, social workers...). Six educational workshops were designed with the following
      endpoints: disease and treatment understanding, treatment management, nutrition and
      psychological as well as physical well being.

      ADOPT-PRESTAGE is a clinical, prospective, interventional, open-label, multicenter,
      randomized, controlled trial designed to evaluate the impact of PRESTAGE program. It is, to
      the investigators' knowledge, the first randomized controlled trial evaluating the
      acceptability and impact (adherence, clinical benefit) of an educational program in an
      elderly cancer population. The primary endpoint of this trial will be to evaluate adherence
      using an indirect objective adherence measure: the Medication Event Monitoring System (MEMS).
      Secondary endpoints include quality of life, evaluation of changes in patients' behaviors and
      economic evaluation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence evaluated by MicroElectronic Monitoring System</measure>
    <time_frame>at 4 months (after intervention or information)</time_frame>
    <description>Adherence will be evaluated with MicroElectronic Monitoring System. A composite score such as described by Thivat et al. in 2013 will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence evaluated by Morisky questionnaires</measure>
    <time_frame>4 months to 12 months</time_frame>
    <description>Results to Morisky questionnaires will be evaluated such as adherence with MEMS, until 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence evaluated by pharmacy medication refill -based adherence</measure>
    <time_frame>4 months to 12 months</time_frame>
    <description>Results to pharmacy medication refill -based adherence will be evaluated such as adherence with MEMS, until 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life evaluated by QLQ-C30 quality of life questionnaire</measure>
    <time_frame>4 months to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life evaluated by the QLQ-ELD14 quality of life questionnaire</measure>
    <time_frame>4 months to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life evaluated by the EORTC quality of life questionnaire</measure>
    <time_frame>4 months to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in patients' behaviors evaluated by questionnaires</measure>
    <time_frame>4 months to 12 months</time_frame>
    <description>Beliefs about Medication questionnaire and satisfaction with medication questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs by micro-costing method</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>planned and unplanned hospitalization rates</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Cancer</condition>
  <condition>Oral Anticancer Drugs</condition>
  <arm_group>
    <arm_group_label>Control arm : Information</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive the usual standard information delivered to patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention arm : Therapeutic educational program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive the therapeutic educational program &quot;PRESTAGE&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PRESTAGE</intervention_name>
    <description>PRESTAGE educational program targets the acquisition by the patients and their caregivers of competencies in (1) a better understanding of their disease and (2) their treatment, (3) a better drug management, including both anticancer and supportive treatments, (4) maintenance of a good nutritional status, (5) general health and psychological well being and (6) physical well being. After an individual educational diagnosis, each patient will be proposed an individualized educational program consisting in 1 to 6 of these workshops. An individualized final interview - entitled educational synthesis - will assess patient's skills and satisfaction.</description>
    <arm_group_label>Intervention arm : Therapeutic educational program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 70 years,

          -  For which oral anticancer therapy has been initiated within the previous 30 days or
             will be started within 30 days

          -  For any type of cancer, solid or hematologic, any stage

          -  Estimated life expectancy&gt; 6 months

          -  Affiliation to social security or equivalent

          -  Patients who can answer questionnaires and protocol evaluations

          -  Informed consent signed by patients

          -  Domiciled within 50 km around the investigating center

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivia LE SAUX</last_name>
    <email>olivia.lesaux@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire FALANDRY, MD</last_name>
    <phone>04 78 86 15 80</phone>
    <phone_ext>+33</phone_ext>
    <email>claire.falandry@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de neuro-oncologie, Hôpital Pierre Wertheimer, HCL</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François DUCRAY, MD</last_name>
      <email>francois.ducray@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>François DUCRAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gériatrie, Centre Hospitalier de Givors</name>
      <address>
        <city>Givors</city>
        <zip>69700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Youri CHAULEUR, MD</last_name>
      <email>ychauleur@ch-givors.fr</email>
    </contact>
    <investigator>
      <last_name>Youri CHAULEUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'oncologie médicale, Centre Hospitalier Universitaire de Grenbole</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hervé CURE, MD</last_name>
      <email>hcure@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé CURE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine du vieillissement, Hôpital Edouard Herriot, HCL</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeth CASTEL-KREMER, MD</last_name>
      <email>elisabeth.castel-kremer@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth CASTEL-KREMER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine LOMBARD-BOHAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas WALTER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de médecine du vieillissement, Hôpital de la Croix-Rousse, HCL</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amandine BRUYAS, MD</last_name>
      <email>amandine.bruyas@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'oncologie médicale, Cnetre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373 cedex 08</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier TREDAN, MD</last_name>
      <email>olivier.tredan@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier TREDAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'oncologie, Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Metz-Tessy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laëtitia STEFANI, MD</last_name>
      <email>lstefani@ch-annecygenevois.fr</email>
    </contact>
    <investigator>
      <last_name>Laëtitia STEFANI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine du vieillissement, Centre Hospitalier Lyon Sud (Hospices Civils de Lyon)</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivia LE SAUX</last_name>
      <email>olivia.lesaux@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Claire FALANDRY, MD</last_name>
      <email>claire.falandry@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Claire FALANDRY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoît YOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis MAILLET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie BONNIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique TRILLET-LENOIR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salima HAMIZI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie TARTAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien PERON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles FREYER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane DALLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phelip GILDAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Jean SOUQUET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de gériatrie, Hôpital de la Charité, Centre Hospitalier Universitaire de St-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2017</study_first_submitted>
  <study_first_submitted_qc>September 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2017</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>therapeutic educational program</keyword>
  <keyword>adherence</keyword>
  <keyword>quality of life</keyword>
  <keyword>elderly</keyword>
  <keyword>cancer</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

